Generic drug: eptifibatide
Brand name: Integrilin
What is Integrilin (eptifibatide), and how does it work?
Integrilin (eptifibatide) injection is a platelet aggregation inhibitor indicated for treatment of acute coronary syndrome (ACS) managed medically or with percutaneous coronary intervention (PCI), and treatment of patients undergoing PCI (including intracoronary stenting). Integrilin injection is available in generic form.
What are the side effects of Integrilin?
Common side effects of Integrilin injection include:
- low blood pressure
Tell your doctor if you have serious side effects of Integrilin injection including:
- easy bruising,
- unusual bleeding (nose, mouth, vagina, or rectum),
- purple or red pinpoint spots under your skin
- blood in your urine
- black, bloody, or tarry stools
- coughing up blood or vomit that looks like coffee grounds
- any bleeding that will not stop
- sudden numbness or weakness, especially on one side of the body
- sudden severe headache, confusion, problems with vision, speech, or balance
- fever, chills, body aches, flu symptoms, or
- feeling like you might pass out.
What is the dosage for Integrilin?
Before infusion of Integrilin, the following laboratory tests should be performed to identify pre-existing hemostatic abnormalities: hematocrit or hemoglobin, platelet count, serum creatinine, and PT/aPTT. In patients undergoing PCI, the activated clotting time (ACT) should also be measured.
The activated partial thromboplastin time (aPTT) should be maintained between 50 and 70 seconds unless PCI is to be performed. In patients treated with heparin, bleeding can be minimized by close monitoring of the aPTT and ACT.
Dosage In Acute Coronary Syndrome (ACS)
|Indication||Normal Renal Function||Creatinine Clearance less than 50 mL/min|
|Patients with ACS||180 mcg/kg intravenous (IV) bolus as soon as possible after diagnosis, followed by continuous infusion of 2 mcg/kg/min||180 mcg/kg IV bolus as soon as possible after diagnosis, followed by continuous infusion of 1 mcg/kg/min|
Integrilin should be given concomitantly with heparin dosed to achieve the following parameters:
During Medical Management
Target aPTT 50 to 70 seconds
- If weight greater than or equal to 70 kg, 5000-unit bolus followed by infusion of 1000 units/h.
- If weight less than 70 kg, 60-units/kg bolus followed by infusion of 12 units/kg/h.
Target ACT 200 to 300 seconds
- If heparin is initiated prior to PCI, additional boluses during PCI to maintain an ACT target of 200 to 300 seconds.
- Heparin infusion after the PCI is discouraged.
Dosage In Percutaneous Coronary Intervention (PCI)
|Indication||Normal Renal Function||Creatinine Clearance less than 50 mL/min|
|Patients with PCI||180 mcg/kg IV bolus immediately before PCI followed by continuous infusion of 2 mcg/kg/min and a second bolus of 180 mcg/kg (given 10 minutes after the first bolus)||180 mcg/kg IV bolus immediately before PCI followed by continuous infusion of 1 mcg/kg/min and a second bolus of 180 mcg/kg (given 10 minutes after the first bolus)|
- Integrilin should be given concomitantly with heparin to achieve a target ACT of 200 to 300 seconds. Administer 60-units/kg bolus initially in patients not treated with heparin within 6 hours prior to PCI.
- Additional boluses during PCI to maintain ACT within target.
- Heparin infusion after the PCI is strongly discouraged.
Patients requiring thrombolytic therapy should discontinue Integrilin.
Important Administration Instructions
- Inspect Integrilin for particulate matter and discoloration prior to administration, whenever solution and container permit.
- May administer Integrilin in the same intravenous line as alteplase, atropine, dobutamine, heparin, lidocaine, meperidine, metoprolol, midazolam, morphine, nitroglycerin, or verapamil. Do not administer Integrilin through the same intravenous line as furosemide.
- May administer Integrilin in the same IV line with 0.9% NaCl or 0.9% NaCl/5% dextrose. With either vehicle, the infusion may also contain up to 60 mEq/L of potassium chloride.
- Withdraw the bolus dose(s) of Integrilin from the 10-mL vial into a syringe. Administer the bolus dose(s) by IV push.
- Immediately following the bolus dose administration, initiate a continuous infusion of Integrilin. When using an intravenous infusion pump, administer Integrilin undiluted directly from the 100-mL vial. Spike the 100mL vial with a vented infusion set. Center the spike within the circle on the stopper top.
- Discard any unused portion left in the vial.
Administer Integrilin by volume according to patient weight (see Table 1).
Table 1: Integrilin Dosing Charts by Weight
|Patient Weight||180-mcg/kgBolus Volume||2-mcg/kg/minInfusion Volume
(CrCl greater than or equal to 50 mL/min)
(CrCl less than 50 mL/min)
|(kg)||(lb)||(from2-mg/mL vial)||(from 2-mg/mL100-mL vial)||(from 0.75-mg/mL100-mL vial)||(from 2-mg/mL100-mL vial)||(from 0.75-mg/mL100-mL vial)|
|37-41||81-91||3.4 mL||2 mL/h||6 mL/h||1 mL/h||3 mL/h|
|42-46||92-102||4 mL||2.5 mL/h||7 mL/h||1.3 mL/h||3.5 mL/h|
|47-53||103-117||4.5 mL||3 mL/h||8 mL/h||1.5 mL/h||4 mL/h|
|54-59||118-130||5 mL||3.5 mL/h||9 mL/h||1.8 mL/h||4.5 mL/h|
|60-65||131-143||5.6 mL||3.8 mL/h||10 mL/h||1.9 mL/h||5 mL/h|
|66-71||144-157||6.2 mL||4 mL/h||11 mL/h||2 mL/h||5.5 mL/h|
|72-78||158-172||6.8 mL||4.5 mL/h||12 mL/h||2.3 mL/h||6 mL/h|
|79-84||173-185||7.3 mL||5 mL/h||13 mL/h||2.5 mL/h||6.5 mL/h|
|85-90||186-198||7.9 mL||5.3 mL/h||14 mL/h||2.7 mL/h||7 mL/h|
|91-96||199-212||8.5 mL||5.6 mL/h||15 mL/h||2.8 mL/h||7.5 mL/h|
|97-103||213-227||9 mL||6 mL/h||16 mL/h||3.0 mL/h||8 mL/h|
|104-109||228-240||9.5 mL||6.4 mL/h||17 mL/h||3.2 mL/h||8.5 mL/h|
|110-115||241-253||10.2 mL||6.8 mL/h||18 mL/h||3.4 mL/h||9 mL/h|
|116-121||254-267||10.7 mL||7 mL/h||19 mL/h||3.5 mL/h||9.5 mL/h|
|>121||>267||11.3 mL||7.5 mL/h||20 mL/h||3.7 mL/h||10 mL/h|
What drugs interact with Integrilin?
Use Of Thrombolytics, Anticoagulants, And Other Antiplatelet Agents
Is Integrilin safe to use while pregnant or breastfeeding?
- Available data on eptifibatide use in pregnant women from published literature and the pharmacovigilance database are insufficient to establish a drug-associated risk of major birth defects, miscarriage or adverse maternal or fetal outcomes.
- Untreated myocardial infarction can be fatal to the pregnant woman and fetus.
- There are no available data on the presence of eptifibatide in human milk, the effects on the breastfed infant, or the effects on milk production.
- As eptifibatide is a peptide, it is likely to be destroyed in the infant's gastrointestinal tract and not absorbed orally by the breastfed infant.
Latest Heart News
Daily Health News
Integrilin (eptifibatide) injection is a platelet aggregation inhibitor indicated for treatment of acute coronary syndrome (ACS) managed medically or with percutaneous coronary intervention (PCI), and treatment of patients undergoing PCI (including intracoronary stenting). Integrilin injection is available in generic form. Common side effects of Integrilin injection include bleeding and low blood pressure.
Multimedia: Slideshows, Images & Quizzes
Heart Disease: Causes of a Heart Attack
Heart disease prevention includes controlling risk factors like diet, exercise, and stress. Heart disease symptoms in women may...
Heart Disease: Foods That Are Bad for Your Heart
If you want a healthy ticker, there are some foods you’ll want to indulge in every now and then only. Find out which ones and how...
Am I Having a Heart Attack? Symptoms of Heart Disease
Heart attacks symptoms vary greatly for men and women, from anxiety and fatigue to nausea and sweating. Learn the warning signs...
Heart Disease: Symptoms, Signs, and Causes
What is heart disease (coronary artery disease)? Learn about the causes of heart disease, arrhythmias and myopathy. Symptoms of...
Heart Disease: How to Help Prevent an AFib Attack
These simple things can make a flare-up of atrial fibrillation less likely.
Heart Disease: Alternative Treatments for AFib
Medication and surgery aren't the only things that can improve or prevent your AFib symptoms. Talk to your doctor about these...
Cardiac Arrest: What You Should Know
Cardiac arrest is a serious medical emergency that requires immediate medical care. Use this WebMD slideshow to know whether you...
Heart Disease: Understand Your Blood and Urine Test Results
Your blood and urine can reveal a lot about your health. Here's how to understand your lab test results.
Heart Disease Quiz: Test Your Medical IQ
Take our Heart Disease Quiz to get answers and facts about high cholesterol, atherosclerosis prevention, and the causes,...
Heart Disease: Best and Worst Foods for Heart Failure
Learn which dietary changes help your heart, and which ones make it work harder.
Heart Disease: Pill-Free Ways to Cut Your Heart Disease Risk
You don't have to take medicine to lower your heart disease risk. Find out more about how diet, exercise, and other lifestyle...
Related Disease Conditions
Heart disease (coronary artery disease) occurs when plaque builds up in the coronary arteries, the vessels that supply blood to the heart. Heart disease can lead to heart attack. Risk factors for heart disease include: Smoking High blood pressure High cholesterol Diabetes Family history Obesity Angina, shortness of breath, and sweating are just a few symptoms that may indicate a heart attack. Treatment of heart disease involves control of heart disease risk factors through lifestyle changes, medications, and/or stenting or bypass surgery. Heart disease can be prevented by controlling heart disease risk factors.
Heart Attack (Myocardial Infarction)
A heart attack happens when a blood clot completely obstructs a coronary artery supplying blood to the heart muscle. A heart attack can cause chest pain, heart failure, and electrical instability of the heart.
Heart Disease: Sudden Cardiac Death
Second Source WebMD Medical Reference
Heart Disease in Women
Heart disease in women has somewhat different symptoms, risk factors, and treatment compared to heart disease in men. Many women and health professionals are not aware of the risk factors for heart disease in women and may delay diagnosis and treatment. Lifestyle factors such as diet, exercise, tobacco use, overweight/obesity, stress, alcohol consumption, and depression influence heart disease risk in women. High blood pressure, high cholesterol, and diabetes also increase women's risk of heart disease. Electrocardiogram (EKG or ECG), stress-ECG, endothelial testing, ankle-brachial index (ABI), echocardiogram, nuclear imaging, electron beam CT, and lab tests to assess blood lipids and biomarkers of inflammation are used to diagnose heart disease. Early diagnosis and treatment of heart disease in women saves lives. Heart disease can be prevented and reversed with lifestyle changes.
Heart Disease Treatment in Women
Heart disease treatment in women should take into account female-specific guidelines that were developed by the American Heart Association. Risk factors and symptoms of heart disease in women differ from those in men. Treatment may include lifestyle modification (diet, exercise, weight management, smoking cessation, stress reduction), medications, percutaneous intervention procedure (PCI), and coronary artery bypass grafting (CABG). Heart disease is reversible with treatment.
Treatment & Diagnosis
- Heart Disease FAQs
- Heart Attack: A Tale of Two Heart Attacks
- Heart Disease - Lessons Learned From Pitcher's Early Death
- Heart Disease Risks Reduced With Running
- Heart Disease In Women
- Heart Disease & Stroke - Progress
- Heart Disease Stroke and Diabetes
- Heart Disease: Antioxidant Supplements and Women
- Hormone Therapy and and Heart Disease in Women
- What are The Complications of Rheumatic Heart Disease?
- Can I Still Get Heart Disease if I Take Blood Pressure Medication?
- Heart Disease Prevention in Women
- Heart Healthy Diet: Hypertension & Heart Disease
Prevention & Wellness
IMAGESBrowse through our medical image collection to see illustrations of human anatomy and physiology See Images
Health Solutions From Our Sponsors
Report Problems to the Food and Drug Administration
You are encouraged to report negative side effects of prescription drugs to the FDA. Visit the FDA MedWatch website or call 1-800-FDA-1088.